Company Overview
 

Medifron DBT, is a clinical stage biopharmaceutical company focusing on the development of Alzheimer's disease (AD) and neuropathic pain (NP) treatment and AD diagnostics.

Since its establishment in 1999, we have been able to license the outcome of the development of new drugs to Big Pharma, including Grünenthal and Roche, and have jointly developed them. This is the evidence that Medifron's technology is recognized in the global market.


 
Company History
 
2016
   ~
2017
  • Out license plan for topical application of neuropathic pain treatment
  • Human clinical trial entry plan for strong analgesics by Grünenthal
  • Developed early diagnosis device for Alzheimer's disease and conducted clinical test for the approval of KFDA & US FDA

2015
  • Collaboration with the National Institutes of Health (NIH), USA
    -  Clinical candidate selection for neuropathic pain treatment (topical application)

2010
  • Roche
    - Research collaboration and out license deals for the treatment of Alzheimer's disease
      (RAGE modulator)
      (Total deal package is $290 million)

2008
  • Daewoong Pharmaceutical
    - Research collaboration and out license deals for the treatment of Alzheimer's disease
      (amyloid beta oligomerization inhibitor)
      (Current stage: phase 1 clinical trial in Korea)

2005
  • Germany Grunenthal Pharmaceuticals
    - Research collaboration and out license deals for non-narcotic strong analgesics
      (Total deal package is €40 million)

1999
  • Establishment of company